Swiss startup Aeon has raised €8.2 million in seed funding to advance its AI-powered preventive health platform aimed at tackling avoidable deaths.
The round was led by Concentric, with backing from several European venture firms and renowned investor Daniel Gutenberg.
Swiss Aeon combines full-body MRI scans, blood biomarker analysis, and genetic testing to detect over 500 conditions at early stages.
The platform boasts a 0 per cent false positive rate in clinical follow-ups, addressing a common issue in preventive medicine while winning the confidence of major insurers.
Its AI platform performs automated imaging analysis, cross-validation, and predictive modelling, offering patients personalised risk profiles and health plans.
With growing insurer partnerships nearly full reimbursement for its check-ups, Aeon is redefining access to care and personalised early detection.
